ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Among the clinically available tyrosine kinase inhibitors (TKIs), some of the most successful to date target the ABL kinases, specifically in the context of BCR-ABL driven chronic myelogenous leukemia (CML) (Table 1).